I
IDEAYA Biosciences
An oncology company, develops cancer therapeutics
About IDEAYA Biosciences
IDEAYA Biosciences is a precision medicine company specializing in oncology, dedicated to discovering and developing targeted therapeutics for specific patient populations identified through molecular diagnostics. The company integrates expertise in identifying and validating translational biomarkers with small molecule drug discovery to select patient populations most likely to benefit from its therapies. IDEAYA operates in the biotechnology and pharmaceutical market, primarily serving healthcare providers and patients with specific cancer types. The business model revolves around research and development, clinical trials, and eventual commercialization of its therapeutic products. Revenue is generated through partnerships, licensing agreements, and sales of approved drugs.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2015
- Headquarters
- South San Francisco, United States
- Listing
- IPO 2019
- Employees
- 261
- Open positions
- 22
- Dealroom signal
- 91.7/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Drug Development, DNA, Genetics and genomics, Genome Engineering, Verified Unicorns and $1B Exits, Post IPO $1B, Biotech and Pharma
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Jun 2026 | $345M | $2.6B | Undisclosed | ↗ |
| POST IPO EQUITYOther financing | Jul 2024 | $302M | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $219M | 0% | −$155M | -70.7% |
| 2025 | $219M | +3024.4% | −$155M | -70.7% |
| 2024 | $7M | -70.1% | −$323M | -4616.3% |
| 2023 | $23M | -54.1% | −$130M | -557.7% |
| 2022 | $51M | +82.3% | −$63M | -122.7% |
| 2021 | $28M | +43% | −$50M | -179.9% |
| 2020 | $20M | — | −$35M | -180.9% |
Growth signals
Latest recorded traffic for IDEAYA Biosciences is 9K monthly website visits, down 40% over the last three months. IDEAYA Biosciences's team grew 16% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
5AM Ventures
Series A14 investors entered at this stage
Bristol-Myers Squibb
Novartis Institutes
Celgene
Canaan
WuXi Healthcare Ventures
Alexandria Equities
6 Dimensions Capital
Nextech Invest
BVF Partners
Perceptive Advisors
Roche Venture Fund
Driehaus Capital Management
Boxer Capital
Centene Corporation
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about IDEAYA Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See IDEAYA Biosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.